To Bathe or Not to Bathe
The Effect of Acute, Passive Heating on Glucose Tolerance in Individuals With Type 2 Diabetes Mellitus: a Randomised, Balanced Crossover, Control Trial
1 other identifier
interventional
20
1 country
1
Brief Summary
Type 2 diabetes mellitus (T2DM) is characterised by chronic high blood sugar concentration (hyperglycaemia) and insulin resistance leading to a reduction in insulin sensitivity. These hyperglycaemic excursions can seriously impact metabolic, micro and macrovascular health. The total cost of the direct and indirect care of individuals with diabetes (\~90% T2DM) in the UK (United Kingdom) is £23.7 billion, equating to \~20% of the annual national health service (NHS) budget, with this projected to become unsustainable. Low-cost interventions to improve glycaemic control in these individuals are therefore warranted. Current interventions include pharmaceuticals, exercise and calorie restrictive diets. Pharmaceutical interventions carry a high financial cost, while exercise and diet programmes have a low adherence rate in individuals with T2DM. Heat therapy offers one potential low cost therapy. Immersion in a hot tub for 30 mins.day-1 for 10 days has been shown to reduce fasting plasma \[glucose\] and HbA1c in individuals with T2DM, which may be explained by acute (e.g. muscle) and chronic (e.g. reduced inflammatory status and increased heat shock proteins (HSP)) adaptations, although experimental evidence for these hypothesis are sparse. Other potential benefits include improved glycaemic control, insulin sensitivity, elevated resting metabolic rate and improved micro- and macrovascular function. The aim of the present study is to determine whether acute hot water immersion can improve glucose tolerance in individuals with T2DM and whether it is more beneficial to undertake this before or after a OGTT (oral glucose tolerance test).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus-type-2
Started Feb 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 20, 2018
CompletedFirst Posted
Study publicly available on registry
January 10, 2019
CompletedStudy Start
First participant enrolled
February 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 9, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 9, 2020
CompletedResults Posted
Study results publicly available
July 19, 2021
CompletedJuly 21, 2021
July 1, 2021
1 year
December 20, 2018
April 29, 2021
July 19, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Mean AUC (Area Under the Curve) Plasma [Glucose]
Does an acute bout of passive, warm water therapy reduce plasma \[glucose\]? Units for AUC are AU (arbitrary units) which have been derived from the trapezoidal method and have been published as such. Trapezoidal method: AUC = Δx ((y0/2)+y1+y2+y3+...+(yn/2)).
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
Secondary Outcomes (6)
Change in Plasma [Insulin]
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
Mean Insulin Sensitivity
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
Change in Fuel Utilisation
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
Change in Cardiovascular Status
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
Change in eHSP70 (Extracellular Heat Shock Protein 70)
Visit 2, 3 and 4. 3 times in total, until study completion, approximately 8 weeks
- +1 more secondary outcomes
Study Arms (3)
Control
NO INTERVENTIONParticipants will lie in a semi recumbent position in minimal clothing for the entirety of the visit. Initially, participants will be cannulated and blood samples drawn.every 30 min of each experimental visit. Following cannulation an 180 min OGTT (75g) will commence in a thermoneutral room (\~ 23C). During the OGTT, HR will be measured continuously, whilst blood pressure, deep body temperature (rectal probe) and resting metabolic rate will be assessed every 30 min.
Pre OGTT
EXPERIMENTALCondition 2 will employ identical procedures to condition 1, except thirty minutes into the OGTT, the participant will be immersed into an immersion tank (\~39oC) for 60 min. Water temperature will be manipulated as required to achieve and maintain a target Trec at 38.5 oC using water between 37.5 and 39oC, and then participants will be removed horizontally back into the thermoneutral room for the reminder of the OGTT. Participants will be towel dried and given a towelled robe to wear.
Post OGTT
EXPERIMENTALCondition 3 will employ identical procedures to condition 2, with the exception that the heating via immersion will start as soon as the participant is instrumented (and following a 15 min rest period) and the OGTT will commence 30 min after the 60 min immersion time for a further 180 min.
Interventions
Eligibility Criteria
You may not qualify if:
- The participant may not enter / be withdrawn from the study if any of the following apply:
- Severe peripheral neuropathy (to the point to which they cannot sense temperature)
- Uncontrolled hypertension (≥180 systolic / 100 diastolic mmHg)
- Taking any medication which may interfere with data interpretation or safety
- Who have had a myocardial infarction or cerebro-vascular event
- Any cardiac abnormalities which restrict hard exercise
- Current smokers or who have stopped within 3 months
- Participant is unable to understand and/or fully cooperate with the study protocol
- Any other serious medical condition which would interfere with data interpretation or safety will be excluded from participation.
- Any skin conditions including ulcerations
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Portsmouthlead
- Portsmouth Hospitals NHS Trustcollaborator
Study Sites (1)
Department of Sport and Exercise Science
Portsmouth, Hampshire, PO1 2ER, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Ant Shepherd
- Organization
- University of Portsmouth
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Senior Lecturer
Study Record Dates
First Submitted
December 20, 2018
First Posted
January 10, 2019
Study Start
February 20, 2019
Primary Completion
March 9, 2020
Study Completion
March 9, 2020
Last Updated
July 21, 2021
Results First Posted
July 19, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will not share
There is no plan to release IPD (individual patient data), until all avenues of further funding have been exhausted.